The Ledger

Forerunner Ventures is about to walk away from Oura with 1.2 billion dollars, and the ring maker itself will keep only a sliver of the money its own initial public offering raises. Oura Inc. filed an amended S-1 registration statement September 21, 2026 for a Nasdaq listing under the ticker OURA, offering 50 million shares priced between 40 and 44 dollars each, which would value the company at approximately 14.1 billion dollars at the midpoint, up from an 11 billion dollar valuation in an October 2025 funding round led by Fidelity. Of those 50 million shares, only 13.5 million are new shares sold by the company; the remaining 36.5 million are secondary shares sold by existing investors, and Forerunner Ventures alone plans to sell its entire 9.3 percent stake, 28.7 million shares, for roughly 1.2 billion dollars, nearly 80 percent of all secondary shares in the offering. At the midpoint price, Oura’s own gross proceeds come to about 567 million dollars, but the filing shows 526.4 million dollars of that is earmarked to cover tax withholding on employee equity awards, leaving the company with roughly 6.2 million dollars for general corporate purposes. The filing also discloses Oura expects to end its fiscal year, September 30, with approximately 5.7 million paying members, nearly double a year earlier, with membership revenue more than doubling to 240.5 million dollars at an 89 percent gross margin, alongside 974 million dollars in hardware revenue. Confidence: High. This run reviewed Oura’s own amended S-1 filing on SEC EDGAR directly, corroborated by a detailed breakdown of the filing’s proceeds allocation. Sources: Oura Inc., Form S-1/A, SEC EDGAR, Oura’s $2.2B IPO is mostly a payday for existing shareholders, TechCrunch.

A Seattle patient-access company just bought its way into the conversations patients have after they leave the exam room, not just the ones that get them into it. DexCare, whose data platform governs patient-access and scheduling tools reaching 57 million patients across health systems, announced September 21, 2026 that it acquired Mila Health, an AI-driven care-coordination startup whose conversational agents autonomously call, text and chat with patients to manage scheduling, pre-visit preparation and post-discharge follow-up. The deal is DexCare’s second acquisition, following its 2022 purchase of Womp, Inc., and extends its AI agents beyond getting patients into the system toward keeping them engaged with their care afterward; financial terms were not disclosed. Confidence: Medium-High. This run relied on trade press reporting of the companies’ own announcement rather than a company filing, since neither DexCare nor Mila Health is publicly traded. Sources: M&A: DexCare Acquires AI Care Coordination Platform Mila Health, HIT Consultant, DexCare Acquires Mila Health, Extending AI Agents From Scheduling to Care Coordination, BusinessWire via FinancialContent.

A gene-therapy company just made four deals in a single day to attack one rare, fatal nerve disease from every angle it could find. Lexeo Therapeutics (Nasdaq: LXEO) announced September 22, 2026 a definitive agreement to acquire Mantle Therapeutics for up to 21.3 million dollars, structured as 8.3 million dollars upfront in cash and equity plus up to 13.0 million dollars in milestone payments tied to clinical and regulatory progress, adding four Friedreich ataxia programs to its pipeline including LX3010, an oral combination therapy that showed roughly a six-point improvement in modified Friedreich Ataxia Rating Scale scores and a nearly ninefold increase in frataxin protein levels in early patient data. Alongside the acquisition, Lexeo announced three new research collaborations, with Weill Cornell Medicine on cerebellar-targeted dosing, with Vivet Therapeutics on an IgG-degrading enzyme, and with Apertura Gene Therapy on a novel central nervous system viral capsid, all meant to complement Lexeo’s lead gene therapy program, LX2006, for Friedreich ataxia cardiomyopathy. Shares rose about 4 percent in premarket trading. Confidence: High on the deal terms, drawn from Lexeo’s own announcement; Medium on the stock reaction, drawn from secondary financial media rather than raw market data reviewed directly this run. Sources: Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics, GlobeNewswire, Lexeo Therapeutics to Acquire Mantle for Up to $21.3M, StockTitan.

Aetna just cut the number of times an oncologist has to ask permission to treat a cancer patient from four down to one. CVS Health’s Aetna announced it is expanding bundled prior authorizations to all cancer types for members in eligible Medicaid states as of September 1, 2026, letting providers submit one round of documentation showing a patient is receiving cancer treatment instead of separate approvals for chemotherapy, radiation, imaging and some immunotherapies; Aetna says providers currently submit four prior authorizations on average over the course of a member’s cancer treatment, and that nearly 25 percent of eligible members have already received a bundled approval since an earlier, narrower rollout. The company plans to extend the bundled process across all of its private plans and its Medicare Advantage plans in the first half of 2027, and says it intends to apply the same model eventually to musculoskeletal conditions like knee and hip problems. Confidence: High. This run reviewed Aetna’s own press release directly. Sources: Aetna expands bundled oncology prior authorizations, easing provider burden and accelerating member access to care, CVS Health.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
Oura Inc. (13.5 million new shares; 36.5 million secondary shares)	Public markets, Nasdaq: OURA	Consumer health wearables	Up to $2.2 billion total offering at $40 to $44 per share; approximately $14.1 billion valuation at midpoint; amended registration filed September 21, 2026	Oura Inc., Form S-1/A, SEC EDGAR
Mila Health	DexCare	AI-driven patient access and care coordination	Undisclosed; announced September 21, 2026	HIT Consultant
Mantle Therapeutics	Lexeo Therapeutics	Gene therapy for Friedreich ataxia	Up to $21.3 million ($8.3 million upfront, up to $13.0 million in milestones); announced September 22, 2026, expected close Q3 2026	GlobeNewswire
Renogen Biolab	XFLH Capital Corporation	DNA and vector engineering services (non-binding letter of intent for a business combination)	Undisclosed; signed September 22, 2026	GlobeNewswire

This run’s scan of FTC and DOJ merger actions and state transaction-review dockets found no new healthcare antitrust complaints or consent decrees in the last 24 to 48 hours; the MultiPlan/Claritev out-of-network repricing multidistrict litigation (MDL 3121) remains in discovery with no new development since this newsletter’s September 17 coverage, and Definitive Healthcare’s special committee still has not publicly responded to Advent International’s September 1 going-private proposal. A frontier check on medical liability and malpractice insurance, a Ledger branch not touched in the last three issues, found Marathon Strategies data reported by Insurance Journal showing verdicts of 10 million dollars or more rose 40.7 percent in 2025 to nearly 200 cases totaling 25.6 billion dollars, but the underlying report published September 7 falls outside this run’s freshness window; worth a full story once an insurer discloses the impact on reserves or premiums. An open-ended scan surfaced HIStalk’s daily industry roundup as the source for two of today’s items; it is added to this newsletter’s digital health source stack as a recurring check.